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drug delivery system that can provide therapeutically 
effective plasma drug concentration levels for longer 
durations, thereby reducing the dosing frequency and 
minimizing fluctuations in the plasma drug concentration 
at a steady state by delivering the drug in a controlled and 
reproducible manner.[6]
On the basis of the mechanism of mucoadhesion,[7,8] 
flotation,[9] sedimentation,[10,11] expansion,[12] modified 
shape system[13,14] or by the simultaneous administration 
of pharmacological agents,[15,16] the controlled gastric 
retention of solid dosage forms may be achieved, which 
delay gastric emptying. In addition to this, a wide variety of 
INTRODUCTION
Drug absorption from a gastrointestinal tract (GI) is a 
complex procedure and is subjected to many variables.[1] 
These variables make the in-vitro performance of the drug 
delivery systems uncertain.[2] The process and ability to 
prolong and control the emptying time is a valuable asset 
for dosage forms, which reside in the stomach for a longer 
period of time than the conventional dosage forms,[3] such 
as, tablets, capsules, and granules. These physiological 
problems have been overcome by several drug delivery 
systems, by investigating the prolonged gastric retention 
time.[4,5] Attempts are being made to develop a controlled 
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ABSTRACT
A multiple-unit floating drug delivery system based on gas formation technique was developed, in order to 
prolong the gastric residence time and to increase the overall bioavailability of the dosage form. The floating 
bead formulations were prepared by dispersing nevirapine together with calcium carbonate in a mixture of sodium 
alginate and hydroxypropyl methylcellulose solution and then dripping the dispersion into an acidified solution of 
calcium chloride. Calcium alginate beads were formed, as the alginate underwent ionotropic gelation by  calcium 
ions, and carbon dioxide developed from the reaction of carbonate salts with acid. The obtained beads were 
able to float due to CO2-gas formation and the gas entrapment by the polymeric membrane. The prepared beads 
were evaluated for percent drug loading, drug entrapment efficiency, morphology, surface topography, buoyancy, 
in-vitro release, and release kinetics. The formulations were optimized for different weight ratios of the gas-
forming agent and sodium alginate. The beads containing higher amounts of calcium carbonate demonstrated 
an instantaneous, complete, and excellent floating ability over a period of 24 hours. The increased amount of the 
gas forming agent did not affect the time to float, but increased the drug release from the floating beads, while 
increasing the coating level of the gas-entrapped membrane, increased the time to float, and slightly retarded 
the drug release. Good floating properties and sustained drug release were achieved. Finally, these floating 
beads seemed to be a promising gastroretentive drug delivery system.
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both natural and synthetic hydrophilic polyionic systems 
such as alginates have been investigated for the preparation 
of multiple unit floating dosage forms (FDF’s).[6]
In the present study, a multiple-unit FDF was designed 
keeping in view the ‘all or nothing’ response of single-unit 
systems.[17] Literature review indicates a widespread use 
of sodium alginate for achieving the sustained release of 
drugs,[18,19]  as it targets the gastric mucosa[20,21] and increase 
the bioavailability of the drugs[22] because of its ability to 
form a stable and bioadhesive gel with calcium ions.[23]
Hydroxy propyl methyl cellulose (HPMC) has been 
reported to enhance the sustained release properties of 
alginate by providing a denser inner matrix.[24] Also the 
preparative methodology of alginate beads involves the use 
of aqueous solvents, avoiding exposure of the ingredients 
to high temperatures and toxic organic solvents;[25-27] 
moreover, the resulting preparation is non-immunogenic, 
with bioadhesive properties that could serve as a potential 
advantage in stomach targeting.
The efficacy and safety of non-nucleoside reverse 
transcription inhibitor (NNRTI)-based regimens have been 
demonstrated in the treatment of HIV-I infected patients. 
The World Health Organization (WHO) recommends 
the use of an NNRTI-based regimen as a first line-anti-
retroviral treatment in source-limited settings, specifically; 
experiences with a generic fixed-dose combination (FDC) 
with nevirapine (NV) have been widely documented in 
resources-limited settings. The mechanism of action is 
that it binds directly to the human immunodeficiency virus 
type I (HIV-I) RT, an RNA-dependent DNA polymerase, 
blocking its function in viral DNA replication.
MATERIALS AND METHODS
Nevirapine (NV) was obtained as a gift sample from 
(Hetero Drugs Pvt. Ltd., Jidimetla, Hyderabad, India), 
Sodium alginate (Loba Chemie Pvt. Ltd., Mumbai, India), 
Hydroxy propyl methyl cellulose (Hymedia Laboratories 
Pvt. Ltd., Mumbai, India), Calcium chloride (Fischer 
Chemie Ltd., Chennai, India), Calcium carbonate (Paxmy 
Speciality Chemicals, Chennai, India), all other reagents 
and chemicals were of analytical grade.
Method of preparation of floating beads of nevirapine 
According to the published procedure,[28] the modified 
procedure for preparing floating beads was as follows; 
0.2 gm of nevirapine was dissolved in 15 ml of methanol. 
This solution was dispersed in 12.5 ml (6 Wt/ Vol) of 
alginate solution containing HPMC (9:1) and then the 
gas forming agent CaCO3 was added to the solution 
in weight ratios of 0 : 1 - 1 : 1 (CaCO3: Alginate w/w) 
[Table 1]. Then the resulting solution was dropped through 
an 18 h (0.8 × 30 mm) syringe needle into 50 ml of CaCl2 
solution, (15% w/v), along with 10% v/v acetic acid. The 
beads were allowed to remain in the same solution for two 
hours to improve their mechanical strength. Next the beads 
were washed, initially with ethanol and subsequently with 
distilled water, and then freeze dried. 
IN-VITRO CHARACTERIZATION
Buoyancy property
The time between the introduction of the beads into the 
medium and its buoyancy to the upper one-third of the 
dissolution vessel and the time for which the formulation 
constantly floated on the surface of the medium (duration 
of buoyancy) were measured simultaneously.[28]
Percentage drug loading
An accurately weighed sample of beads (10 mg) was 
crushed in a mortar and added to 10 ml of 0.01N HCl. 
This mixture was centrifuged at 4200 rpm for 30 minutes, 
filtered and analyzed spectrophotometrically at λmax 281 
nm against 0.01N HCl[28] as blank. The above-mentioned 
procedure was carried out with the blank beads. This was 
calculated by dividing the amount of drug in the sample 
beads by weight of the beads.
Table 1: Formulation variables and evaluation parameters of various Nevirapine floating bead formulations (NV-No 
gas forming agent, NV1-0.5% gas forming agent, NV2-0.75% gas forming agent, NV3-1:1 gas forming agent)
Formulation Calcium carbonate: Sodium 
Alginate (wt/wt)
Mean surface diameter Moisture Content (%)*
Wet * Dry*
NV 0:1 1.53 ± 0.02 0.0848 ± 0.0002 19.526 ± 0.01
NV1 0.5:1 2.74 ± 0.03 0.0105 ± 0.0002 12.806 ± 0.01
NV2 0.75:1 2.85 ± 0.05 0.0967 ± 0.0004 16.616 ± 0.02
NV3 1:1 3.04 ± 0.02 0.0907 ± 0.0003 17.883 ± 0.02
*All the values are expressed as mean ± SEVedha Hari, et al. J Young Pharm. 2010;2(4): 350-355
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% Drug loading = (Amount of drug present) / (Total 
weight of beads) x 100.
Particle size
The particle size distribution of the beads was evaluated 
by sieve analysis.[29] One hundred grams of the beads were 
weighed and sieved through a set of sieves No: (12, 16, 
18, 22, and 25) on a vibratory sieve shaker (PritecAC-99, 
M.B. Instruments, Delhi-7, India.) for 20 minutes, and the 
weight distribution was determined.
Drug entrapment efficiency
An accurately weighed sample of beads (10 mg) was 
crushed in a mortar and added to 10 ml of 0.01N HCl. 
This mixture was sonicated for 30 minutes, filtered and 
analyzed spectrophotometrically at λmax 281nm against 
0.01N HCl as blank.[30]
%EE = (Amount of added drug - Amount of non 
encapsulated drug) / (Amount of added drug) x100.
Moisture content
The moisture content of the formulated beads was 
determined using the procedure.[31] The moisture in a wet 
solid is that calculated on a dry weight basis; this value is 
referred to as moisture content.
% Moisture content = (wt. of water in sample) / (wt. of 
dry sample) × 100.
Infrared (IR) spectroscopy analysis
The sample preparation includes grinding a quantity of 
the sample with a specially purified salt (usually potassium 
bromide) finely (to remove scattering effects from large 
crystals). This powder mixture is then crushed in a 
mechanical die press to form a translucent pellet,[32] through 
which the beam of the spectrometer can pass. This makes 
the observations of chemical reactions and processes 
quicker and more accurate.
In-vitro release studies
An accurately weighed sample (40 mg) of a floating bead 
formulation was dropped in 900ml of 0.01 N HCl,[28] 
maintained at a temperature of 37ºC  ±  0.5oC and stirred 
at a speed of 50 rpm using USP dissolution apparatus type 
I (Basket). At different time intervals, a 10 ml aliquot of the 
sample was withdrawn and the same volume was replaced 
with an equal amount of plain dissolution medium. The 
collected samples were filtered and analyzed at λmax 281 
nm, using a UV spectrophotometer against the medium 
buffer as a blank.
RESULTS AND DISCUSSION
Drug Entrapment efficiency (EE)
The percentage of drug entrapment efficiency was found 
to be (85.33, 75.66, 69.00, and 64.33) for the ratios of 0 : 
1, 0.5 : 1, 0.75 : 1, and 1 : 1 by increasing the concentration 
of the CaCO3 : alginate ratio. There was a decrease in drug 
entrapment because of the release of CO2. The reaction 
between CaCO3 and acetic acid led to the release of CO2, 
which penetrated the matrix of the alginate. Thus the 
porous beads resulted in decreased entrapment efficiency 
of the drug. The bead without CaCO3 attained high EE, 
which could be because of the highly dense internal 
structure of the alginate matrix.[28] 
Buoyancy properties
The floating ability was carried out for 24 hours and the 
data is tabulated in Table 2. We could see partial sinking 
in the formulation of NV1, but the formulations of NV2 
and NV3 were floating completely throughout the study 
period. This might be due to the high concentration of 
the gas forming agent, because the floating ability was   
found to be directly related to the gas content of the   
matrix.[28] 
Particle size
The optical microscope images show that the formulated 
beads are spherical in shape and some show some rough 
surfaces [Figure 1], the particle size is determined by 
the sieve technique, using standard sieves (mesh) on an 
electrically equipped shaker for 15 minutes. The settled 
fractions were collected after weighing them individually, 
the particle size was calculated, and the mean particle size 
was between the range of 0.089 and 1.052 mm. 
Drug loading
The percentage drug loading of the different floating 
beads of nevirapine ranged between 23.6 and 35.87. It 
could be seen that by increasing the concentration of the 
gas forming agent, there was a decrease in drug loading.[28]
Moisture content
The moisture content of the formulated beads was Drug delivery of nevirapine as a gastroretentive system
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calculated by the proposed procedure.[31] The moisture 
in a wet solid was calculated on a dry weight basis, it was 
between 12.806 and 19.526 [Table 1].
FT-IR spectral analysis
The FT-IR Spectrum of formulation NV2 is shown in 
Figures 2-4. The spectra reveal drug characteristics such 
as C=O (3432.82), N=C (1645.90) and NH (1548.76). The 
NH bond in plane (1463.69) shows the presence of the 
drug, with no interaction, and also the disappearance of 
some of the peaks in the formulation, which could be the 
encapsulation of the sodium alginate polymer. 
In-vitro drug release
The nevirapine-loaded alginate beads were evaluated for 
drug release using 0.01NHCl (pH 1.2) as the dissolution 
media. The percentage drug release was (17.03, 18.32, 
19.69, 26.82) for NV, NV1, NV2, and NV3, respectively, up 
Figure 1: Nevirapine (pure)
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Figure 2: Blank floating Beads (without drugs)
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Table 2: Evaluation parameters of various Nevirapine floating bead formulations (NV-No gas forming agent, NV1-
0.5% gas forming agent, NV2-0.75% gas forming agent, NV3-1:1 gas forming agent) Completely sink (+ +), 
partially sink (+, completely float (- -)
Formulation Floatation Property Duration floatation % drug loading* % drug entrapment* % release*
NV (+ +) 24 hrs 35.87 ± 0.024 85.33 ± 3.29 17.03 ± 0.03
NV1 (+ -) 24 hrs 31.07 ± 0.028 75.66 ± 2.86 18.32 ± 0.03
NV2 (- -) 24 hrs 27.66 ± 0.020 69 ± 2.44 19.69 ± 0.02
NV3 (- -) 24 hrs 23.60 ± 0.036 64.33 ± 3.68 26.82 ± 0.02
*All the values are expressed as mean ± SE
Figure 4: Effect of concentration of gas forming agent on in-vitro release 
of nevirapine from prepared floating beads
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Figure 3: NV2 (0.75:1)Table 1
Sample Name: Blank
4000.0 3000 2000 1500 1000 4500
16.92
17.5
18.0
18.5
19.0
19.5
20.0
20.5
21.0
21.5
22.0
22.5
23.0
23.5
24.0
24.5
25.0
25.5
26.0
26.67
cm-1
%
T
 
3374.87
1634.74
1548.68
1462.77
1017.68
665.05
Date: 08/10/09Vedha Hari, et al. J Young Pharm. 2010;2(4): 350-355
354   Journal of Young Pharmacists Vol 2 / No 4
Table 3: Release kinetics of drug release from 
Nevirapine floating beads (NV-No gas forming agent, 
NV1-0.5% gas forming agent, NV2-0.75% gas forming 
agent, NV3-1:1 gas forming agent)
Ratio NV NV1 NV2 NV3
Zero order 0.9219 0.9719 0.9726 0.9482
First order 0.8513 0.8513 0.8513 0.8513
Higuchi 0.9771 0.9721 0.9621 0.9953
Korsmeyer 0.9747 0.9635 0.9695 0.9789
Hixson 0.9284 0.9763 0.9773 0.9583
to 12 hours [Figure 5], by using USP dissolution apparatus 
type-I (Basket). There was an increase in the release rate, 
with an increase of the gas-forming agent (CaCO3). This 
could be due to the pores present on the surface of the 
beads. Moreover, because of the more effective entrapment 
of the drug in the highly dense external structure of the 
alginate, the beads exhibited slow and extended release 
of the drug after 12 hours. The increased density of the 
polymer matrix at higher concentrations resulted in an 
increased diffusional path length, and due to this there 
could be a decrease in the overall drug release. 
The gas forming agent was added at various concentrations 
to make the beads float in the medium. It was absorbed 
by the increased concentration of the gas forming agent, 
CaCO3, and keeping the alginate at a constant, from 0.5 : 
1 (NV1) to 1 : 1(NV3) there was an increase in buoyancy 
and there was an increase in drug release when compared 
with the formulation without the gas forming agent 0 : 1 
(NV) (17.03%).
The data obtained for in-vitro release were fitted into 
equations for the zero order and first order, in the Higuchi, 
Korsmeyer, and Hixson release models; the interpretation 
of the data was based on the value of the resulting 
regression co-efficient [Table 3]. The in-vitro drug release 
showed the highest regression value for the Higuchi model, 
indicating diffraction to be the predominant mechanism 
of drug release. 
CONCLUSION
It was observed that the formulation that contained the gas 
forming agent and drug ratio NV2 (0.75 : 1) was optimum, 
with respect to the floating ability, prolonged and sustained 
release, which was confirmed, as it obeyed the Higuchi 
(NV2) release kinetics. This above-mentioned formulation 
(NV2) could be a suitable composition for nevirapine, as a 
floating gastroretentive dosage form. To better understand 
the mechanism and drug release, in-vivo studies will have to 
be carried out in future.
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